Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016', provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics. 

The report provides comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) 
- The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview 7
Therapeutics Development 8
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Stage of Development 8
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Therapy Area 9
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Indication 10
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Companies 15
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Products under Development by Universities/Institutes 17
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Companies Involved in Therapeutics Development 26
Merck & Co Inc 26
SciFluor Life Sciences LLC 27
SOM Biotech SL 28
Tissue Therapies Ltd 29
TWi Pharmaceuticals Inc 30
Vascular Pharmaceuticals Inc 31
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Drug Profiles 32
A-11 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AC-301 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
C-16Y - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
cilengitide - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MK-0429 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
OCU-200 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Proagio - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Recombinant Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
RSF-201 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
RUC-4 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
SF-0166 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
SOM-0777 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
tetraiodothyroacetic acid - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
VF-001 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
VPI-2690B - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Dormant Projects 50
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Discontinued Products 55
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Featured News & Press Releases 56
Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001) 56
Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution 56
Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US 57
Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board 57
Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases 59
May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find 60
May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 61
Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av�3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease 61
Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 62
Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update 63
Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma 64
Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide's Pivotal Phase III Trial CENTRIC 65
Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients 66
May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma 67
Mar 16, 2009: Merck Serono Expands Cilengitide Development Program 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by Merck & Co Inc, H2 2016 26
Pipeline by SciFluor Life Sciences LLC, H2 2016 27
Pipeline by SOM Biotech SL, H2 2016 28
Pipeline by Tissue Therapies Ltd, H2 2016 29
Pipeline by TWi Pharmaceuticals Inc, H2 2016 30
Pipeline by Vascular Pharmaceuticals Inc, H2 2016 31
Dormant Projects, H2 2016 50
Dormant Projects (Contd..1), H2 2016 51
Dormant Projects (Contd..2), H2 2016 52
Dormant Projects (Contd..3), H2 2016 53
Dormant Projects (Contd..4), H2 2016 54
Discontinued Products, H2 2016 55